ClearPoint Neuro Congratulates Its Partner PTC Therapeutics On Completion Of Biologics License Application Submission To FDA For Upstaza As A Treatment For AADC Deficiency
Portfolio Pulse from Benzinga Newsdesk
ClearPoint Neuro, Inc. (CLPT) congratulates its partner PTC Therapeutics on the completion of a Biologics License Application (BLA) submission to the FDA for Upstaza, a treatment for AADC Deficiency. If approved, Upstaza would be the first therapy for this condition in the U.S. AADC Deficiency is a rare, fatal genetic disorder causing severe disability from birth. ClearPoint's SmartFlow Cannula, used in delivering gene therapies to the brain, has been sold over 7,000 times and is part of their partnership with PTC Therapeutics.
March 19, 2024 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ClearPoint Neuro's partnership with PTC Therapeutics and the submission of Upstaza for FDA approval could positively impact CLPT, highlighting its role in enabling gene therapy delivery.
The news of the BLA submission for Upstaza by PTC Therapeutics, in partnership with ClearPoint Neuro, is likely to be viewed positively by investors. ClearPoint's SmartFlow Cannula technology, integral to delivering gene therapies like Upstaza, demonstrates the company's critical role in the development and potential commercialization of treatments for rare genetic disorders. This development could lead to increased investor confidence in ClearPoint's technology and partnerships, potentially boosting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90